Healthcare Losers: Athersys, Inc. (NASDAQ:ATHX), Zogenix (NASDAQ:ZGNX), Therapeutics MD (NYSEMKT:TXMD), Insmed Incorporated (NASDAQ:INSM)

Athersys (NASDAQ:ATHX) had its price target cut by Maxim Group from $10.00 to $7.00. Maxim Group currently has a buy rating on the stock. Athersys, Inc.(NASDAQ:ATHX) shares after opening at $1.27 moved to $1.33 on last trade day and at the end of the day closed at $1.33 Company price to sales ratio in past twelve months was calculated as 42.73 and price to cash ratio as 3.21. Athersys, Inc. (NASDAQ:ATHX) showed a negative weekly performance of -52.33%.

Stifel Nicolaus reissued their buy rating on shares of Zogenix (NASDAQ:ZGNX) in a research report sent to investors on Friday morning, Analyst Ratings Network reports. The firm currently has a $5.00 price target on the stock. Zogenix, Inc. (NASDAQ:ZGNX) shares fell -5.54% in last trading session and ended the day on $2.56. ZGNX return on assets is 142.56%. Zogenix, Inc. (NASDAQ:ZGNX) yearly performance is 51.48%.

TherapeuticsMD, Inc. (NYSEMKT:TXMD), a women’s healthcare company will host a conference call and live audio webcast to disclose its financial results for the quarter ended March 31, 2014. The call and webcast will be held on Monday, May 5, 2014 at 4:30pm EDT and will be hosted by Robert Finizio, Co-Founder and Chief Executive Officer, and Dan Cartwright, Chief Financial Officer. Therapeutics MD Inc (NYSEMKT:TXMD) shares moved down -7.06% in last trading session and was closed at $4.08, while trading in range of $ 3.99 – 4.45.Therapeutics MD Inc (NYSEMKT:TXMD) year to date (YTD) performance is -21.69%.

Insmed (NASDAQ:INSM)‘s stock had its “overweight” rating restated by stock analysts at Piper Jaffray in a report issued on Wednesday, Analyst Ratings Network reports. They currently have a $51.00 target price on the stock. Piper Jaffray’s price target would indicate a potential upside of 263.25% from the stock’s previous close. Insmed Incorporated (NASDAQ:INSM) weekly performance is -12.11%. On last trading day company shares ended up 12.70 $. Insmed Incorporated (NASDAQ:INSM) distance from 50-day simple moving average (SMA50) is -26.96%. Analysts mean target price for the company is $29.14.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *